Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Chondrosarcoma and Clear Cell Sarcoma
NCT04458922Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in chondrosarcoma, clear cell sarcoma (CCS), sponsored by National Cancer Institute. Started Oct 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
chondrosarcomaclear cell sarcoma (CCS)
Beyond the preview
Go deeper on NCT04458922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458922.